PolyTherics and MacroGenics Extend Collaboration to Produce Novel Antibody Drug Conjugates

April 11, 2014

LONDON, April 11, 2014 /PRNewswire/ –

ThioBridge(TM) linker to attach different payloads to a range of antibodies

PolyTherics Limited (“PolyTherics”), a provider of technologies and services to enable
the development of better biopharmaceuticals, today announced an extension to its
ThioBridge(TM) antibody drug conjugate (“ADC”) collaboration with MacroGenics Inc (NASDAQ:
MGNX), a US biotechnology company developing innovative medicines utilizing its next
generation antibody technologies.

PolyTherics has developed ThioBridge(TM) for site-specific conjugation of cytotoxic
payloads to antibodies to provide more stable and less heterogeneous ADCs. MacroGenics has
two antibody technology platforms, a Dual-Affinity Re-Targeting (DART(TM)) bi-specific
platform, in which a single recombinant molecule is able to target two different antigens,
and Fc-optimized antibodies with improved effector function.

The collaboration was extended following the successful outcome of a research
programme undertaken in 2013 under a Research Collaboration and Option Agreement, in which
ThioBridge(TM) was used to conjugate a cytotoxic payload to a range of DART antibodies.
MacroGenics and PolyTherics will collaborate in the application of its ThioBridge(TM)
technology to a number of product candidates derived from MacroGenics’ antibody platforms.
MacroGenics has an option to licence the ThioBridge(TM) technology for the development of
these product candidates and PolyTherics would receive development milestones and a
single-digit percentage royalty on sales of any ThioBridge(TM) ADC derived from this

John Burt, CEO of PolyTherics, commented “We are pleased with the success of our
initial work with MacroGenics’ antibodies and their extension of the collaboration to a
wider range of antibodies and payloads endorses their support for the versatility of
ThioBridge(TM) and its use to produce better ADCs.”

About PolyTherics

PolyTherics provides technology solutions to enable the development of better
biopharmaceuticals and offers a portfolio of proprietary and complementary technologies
and services to address key needs in biopharmaceutical development.

PolyTherics’ portfolio of services and technologies includes proprietary site-specific
conjugation technologies and novel polymers for optimising the therapeutic properties of
biopharmaceuticals and through its Cambridge, UK-based subsidiary, Antitope, services for
protein immunogenicity assessment and antibody and protein re-engineering technologies are
delivered. The group provides its services and technologies to an international client
base that includes most of the world’s leading biotechnology and pharmaceutical companies.

PolyTherics is a privately owned UK company backed by institutional investors
including Imperial Innovations (AIM: IVO), Invesco Perpetual, Mercia Fund Management,
Advantage Enterprise & Innovation Fund (managed by Catapult Venture Partners), ProVen
Health, Oxford Technology VCTs and high net worth individuals’ funds managed by Longbow
Capital. The Company has dedicated facilities in London, Cambridge and Coventry, UK.


        For more information, please contact:

        John Burt, PolyTherics
        Tel: +44(0)20-7691-3580
        Email: john.burt@polytherics.com

        Mark Swallow, Sita Shah or Chris Gardner, Citigate Dewe Rogerson
        Tel: +44(0)20-7638-9571
        Email: mark.swallow@citigatedr.co.uk

SOURCE PolyTherics

Source: PR Newswire

comments powered by Disqus